Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
12 Jul, 2022 (Tuesday)

            
YOFC(6869)
Analysis:
Yangtze Optical Fibre and Cable (6869) is principally engaged in the manufacture and sales of optical fibre preforms, optical fibres and optical fibre cables with various standard specifications that are widely used in the telecommunications industry and the provision of other related products and services. Regarding optical fibres and optical fibre cables, applications such as telecommuting, online entertainment and virtual reality are expanding, and people`s demand for mobile and fixed network bandwidth is increasing, promoting operators to strengthen construction. While consolidating the leading edge of its main business, the Group has continuously accelerated the pace of diversification in recent years and achieved the breakthrough in many fields. For instance, EverPro, a subsidiary of the Group occupied in opto chips, modules, AOC, comprehensive wiring and other related businesses, has made continuous breakthroughs in application fields such as ultra-high definition video, virtual reality, medical system, machine vision and data center, and its products have entered the supply chain of many famous large overseas customers. (I do not hold the above stock)
Strategy:
Buy-in Price: $13.00, Target Price: $14.60, Cut Loss Price: $12.20


CLOVER BIO(2197)
Analysis:
Clover Biopharmaceuticals(02197)announce that new positive clinical data in individuals vaccinated with a third dose of SCB-2019 (CpG 1018/Alum) as a homologous booster against the Omicron variant. In this study, a homologous booster dose of SCB-2019 in individuals who previously received two doses of SCB-2019 induced a robust and rapid neutralizing antibody immune response in this preliminary analysis. A cohort comprised of individuals who were baseline seronegative demonstrated a robust 19-fold increase against the Omicron BA.2 variant and a 12-fold increase in neutralizing antibodies against the Omicron BA.1 variant compared to pre-booster levels. In total, 3,755 participants were recruited in Brazil, the Philippines and Columbia. The Company will further evaluate study participants for immunogenicity, durability, and safety. Meanwhile, the company remains focused on completing regulatory submissions to the National Medical Products Administration of China, the European Medicines Agency, and the World Health Organization for SCB-2019 (CpG 1018/Alum) in the second half of 2022, while concurrently preparing for global commercialization.
Strategy:
Buy-in Price: $4.64, Target Price: $5.50, Cut Loss Price: $4.04



BYD (1211.HK) - Hit New High!

Investment Summary

Sales Volume Soars by 163% YoY in June

The latest sales data show that BYD's new energy vehicle sales hit another record high in June: a total of 134,036 new energy vehicles were sold, up163% yoy and 17% mom, which is expected to be higher than the overall rise in domestic new energy vehicles. The cumulative sales volume for the first six months was 641,350 units, up 314.9% yoy, reaching 43% of the annual sales target of 1,500thousand units.

From the perspective of different types, the sales volume of new energy commercial vehicles was 274 units in June, down 78% yoy and 64% mom. The sales volume of pure electric passenger vehicles was 69,544 units, up 247% yoy and 30% mom, while the sales volume of plug-in hybrid electric vehicles was 64,218 units, up 219.5% yoy and 5.6% mom. The cumulative sales volume for the first six months was 323,519 and 314,638 units, respectively, up 246% yoy and 454% yoy. The former was mainly driven by the expansion of production at the Shenzhen plant, while the latter's slightly lower yoy growth was due to the impact of the shutdown of the Changsha plant for investigation..

A Number of Models Continue to Be Sold Well, and New Vehicle Models Are Launched Intensively

The overall vehicle market picked up in June as the resumption of work and production continued. With strong product competitiveness, the flagship model of the Dynasty series, Han, saw hot sales, recording sharp increases for several months in a row. In June, its sales volume exceeded 20 thousand units for two consecutive months, reaching 25,439 units, up 203% yoy, of which the delivery of Han DMI was up 386% yoy and that of Han EV closed to 13 thousand units. The cumulative sales volume for the first six months exceeded 250 thousand units, continuing to lead the sedan segment of the same class.

The sales of other models of the Dynasty series was also high: 8,134/26,623/32,077/19,731 units of the Tang/Qin/Song/Yuan series were sold in June, up 159%/71.7%/113%/1494% yoy, with a cumulative sales volume of 55,825/146,737/163,356/78,662 units in the first six months.

In addition, the Destroyer 05/Dolphin/e series recorded a sales of 7,464/10,376/3,918 units, respectively.

This year and next are major product years for BYD, which is expected to launch no less than 20 new vehicle models in total, including facelifts. This year, the Destroyer 05, Seal, Denza D9, 22 Tang EVs, 22 Han EVs, DM-i, DM-p and Qin Plus DM-i have already been launched, and in the second half of the year and next year, BYD will continue to launch Denza SUVs, the Warship series, Sea Lion and Seagull. The product matrix will be further improved and, judging from the current optimistic pre-sale situation, the product unit price is expected to continue to see upward breakthrough.

Continuous Capacity Release with Firm Policy Support

Since May, the Chinese government has announced a new round of new energy vehicles to the countryside, and the meeting of the State Council held in June explicitly supported the consumption of new energy vehicles and considered extending the preferential policy of exemption from the purchase tax on new energy vehicles, involving a total of 69 models from 26 vehicle companies, further expanding the coverage compared to 2021 (52 models from 18 brands in 2021). The local government has granted more subsidies to new energy vehicles compared to traditional fuel vehicles, reflecting the government's firm determination to the countercyclical adjustment and its resolute support for the development of the new energy vehicle industry. The renovation of the new plant in Changzhou and the Shenzhen plant and the second phase of the Changsha plant and the new plant in Hefei are expected to further release production capacity, which, coupled with the Company's long-term control of the supply chain, will provide strong support for the achievement of the annual sales target and may even beat expectations.

Investment Thesis

Therefore, although there are various challenges in the future, we believe that the Company is entering into a growth period with more stability and sustainability.

In terms of STOP valuation adopt, we give the original business (automobile, mobile phone, rechargeable battery and photovoltaic business) 296/230 HK$/per share, power battery business and semiconductor business from two assumptions of optimistic expectation and cautious expectation, and 173/89 and 5.5/2.5 HK$/per share, the overall valuation is respectively 477/321 HK$/per share, implying 47% and -1% upside respectively. For comprehensive consideration, we given the target price of 399 HK$, corresponding to 2022/2023/2024 127.5/74/53x P/E, 9.6/8.5/7.4x P/B, BUY rating. (Closing price as at 7 July)

Risk

Sales of NEVs is not as good as expected

New business risk

Slow-down of Hand-set components business

Financials

Click Here for PDF format...




Recommendation on 12-7-2022
RecommendationBUY
Price on Recommendation Date$ 325.000
Suggested purchase priceN/A
Target Price$ 399.000
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2022 Phillip Securities (HK) Ltd. All Rights Reserved.